Which New Diagnostics for Tuberculosis, and When?

被引:53
作者
Cobelens, Frank [1 ,2 ]
van den Hof, Susan [1 ,2 ,3 ]
Pai, Madhukar [4 ]
Squire, S. Bertel [5 ]
Ramsay, Andrew [6 ]
Kimerling, Michael E. [7 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands
[2] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands
[3] KNCV TB Fdn, The Hague, Netherlands
[4] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[5] Univ Liverpool Liverpool Sch Trop Med, Clin Res Grp, Liverpool, Merseyside, England
[6] WHO, United Nations Childrens Fund, United Nations Dev Programme, World Bank,World Hlth Org WHO Special Programme R, CH-1211 Geneva, Switzerland
[7] Bill & Melinda Gates Fdn, Seattle, WA USA
基金
比尔及梅琳达.盖茨基金会;
关键词
RESISTANT TUBERCULOSIS; IMPLEMENTATION; RECOMMENDATIONS; CHALLENGES; BIOMARKERS; ACCURACY; STRENGTH; QUALITY; GRADE; NEEDS;
D O I
10.1093/infdis/jis188
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.
引用
收藏
页码:S191 / S198
页数:8
相关论文
共 33 条
[1]  
[Anonymous], PATHW BETT DIAGN TUB
[2]  
[Anonymous], 2011, COMMERCIAL SERODIAGN
[3]  
[Anonymous], TB DIAGN LAB STRENGT
[4]  
[Anonymous], 2008, REV ESP SALUD PUBLIC
[5]  
[Anonymous], WHOHTMTB20119
[6]   Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa [J].
Barnard, Marinus ;
Allbert, Heidi ;
Coetzee, Gerrit ;
O'Brien, Richard ;
Bosiman, Marlein E. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (07) :787-792
[7]   Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study [J].
Boehme, Catharina C. ;
Nicol, Mark P. ;
Nabeta, Pamela ;
Michael, Joy S. ;
Gotuzzo, Eduardo ;
Tahirli, Rasim ;
Gler, Ma Tarcela ;
Blakemore, Robert ;
Worodria, William ;
Gray, Christen ;
Huang, Laurence ;
Caceres, Tatiana ;
Mehdiyev, Rafail ;
Raymond, Lawrence ;
Whitelaw, Andrew ;
Sagadevan, Kalaiselvan ;
Alexander, Heather ;
Albert, Heidi ;
Cobelens, Frank ;
Cox, Helen ;
Alland, David ;
Perkins, Mark D. .
LANCET, 2011, 377 (9776) :1495-1505
[8]   Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis [J].
Dowdy, David W. ;
Steingart, Karen R. ;
Pai, Madhukar .
PLOS MEDICINE, 2011, 8 (08)
[9]   GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations [J].
Guyatt, Gordon H. ;
Oxman, Andrew D. ;
Vist, Gunn E. ;
Kunz, Regina ;
Falck-Ytter, Yngve ;
Alonso-Coello, Pablo ;
Schuenemann, Holger J. .
BRITISH MEDICAL JOURNAL, 2008, 336 (7650) :924-926
[10]   Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults [J].
Koole, Olivier ;
Thai, Sopheak ;
Khun, Kim Eam ;
Pe, Reaksmey ;
van Griensven, Johan ;
Apers, Ludwig ;
Van den Ende, Jef ;
Mao, Tan Eang ;
Lynen, Lutgarde .
PLOS ONE, 2011, 6 (04)